Non-motor symptoms in myasthenia gravis
Keywords:
Myasthenia gravis, non-motor symptoms, fatigue, sleep, depression, anxiety, comorbidityAbstract
Myasthenia gravis /MG/ is an autoimmune disease characterized by pathological fatigue of the skeletal muscles and muscle weakness, which increases during the day. Along with motor, non-motor symptoms such as fatigue, sleep disturbances, psychiatric disorders and autoimmune comorbidities are often observed. Unusually, they have a greater significance in the clinical practice than muscle fatigue, but are significantly underestimated and not sufficiently studied and described in the literature. A link between fatigue and sleep disorders, as well as the presence of depression and anxiety in many of MG patients, has been proven. A relationship between non-motor symptoms and the possibility of developing a myasthenic crisis is also found. MG patients are exposed to a greater risk of developing another autoimmune disease, like most commonly thyroid gland diseases, rheumatoid arthritis, systemic lupus erythematosus, etc. Early diagnosis of the non-motor symptoms in MG is necessary, as their study and treatment would greatly improve the quality of life of the patients.
References
[Deneva, V. Miastenni krizi-diagnostika,monitorirane i savremenni terapevtichni podhodi, Avtoreferat na Disertatsiya za prisazhdane na nauchnata stepen „Doktor na naukite”, Sofia, 2017].
[Milanov, I. Nevrologia. Milanov, I., Varna, IK Steno, 2021].
Alanazy, MH. Prevalence and associated factors of depressive symptoms in patients with myasthenia gravis: a cross-sectional study of two tertiary hospitals in Riyadh, Saudi Arabia. Behav Neurol, 2019, 453.
Alekseeva, T., Gavrilov, Y., Kreis, O., Valko, P., Weber, K., Valko, Y. Fatigue in patients with myasthenia gravis. J Neurol, 2018, 2312-2321.
Andersen, J., Owe, J., Engeland, A., Gilhus, N. Total drug treatment and comorbidity in myasthenia gravis; a population-base cohort study. Eur J Neurol, 2014. 948-995.
Avidan, N., Le Panse, R., Harbo, H., Bernasconi,P., Poulas, K., Ginzburg, E., Miller, A. VAV1 and BAFF, via NFkappaB pathway, are genetic risk factors for myasthenia gravis. Annals of Clinical and Translational Neurology, 2014, 329-339.
Bartel, P., Lotz, B. Neuropsychological test performance and affect in myasthenia gravis. Acta Neurol Scand,1995, 266-270.
Basta, I., Pekmezović ,T., Perić, S., Kisić-Tepavčević, D., Rakočević-Stojanović, V., Stević, Z., Lavrnić, D. Assessment of healthrelated quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurol Sci, 2012, 1375-1381.
Blazer, D., Kessler, R., McGonagle, K., Swartz, M.The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry, 1994, 979-986.
Blum, S., Lee ,D., Gillis, D., McEniery, D., Reddel, S., Mc-Combe, P. Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci, 2015, 1164-1169.
Chaudhuri, A., Behan, P. Fatigue in neurological disorders. Lancet, 2004, 978-988.
Elsais, A., Wyller, V., Loge ,J., Kerty, E. Fatigue in myasthenia gravis: is it more than muscular weakness? BMC Neurol, 2013, 132.
Fang ,F., Sveinsson, O., Thormar, G., Granqvist, M., Askling, J., Lundberg, I., Ye ,W., Hammarström, L., et al. The autoimmune spectrum of myasthenia gravis: a Swedish population-based study. J Intern Med, 2015, 594-604.
Fisher, J., Parkinson, K., Kothari, M. Self-reported depressive symptoms in myasthenia gravis. J Clin Neuromuscul Dis., 2003, 105-108.
Gavrilov, Y., Alekseeva, T., Kreis, O., Valko, P., Weber, K., Valko,Y. Depression in myasthenia gravis: a heterogeneous and intriguing entity. J Neurol., 2020, 1802-1811.
Hoffmann, S., Ramm, J., Grittner, U., Kohler, S., Siedler, J., Meisel, A. Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav., 2016, 538.
Kubiszewska, J., Szyluk, B., Szczudlik ,P., Bartoszewicz, Z., Dutkiewicz, M., Bielecki, M., Bednarczuk, T., Kostera-Pruszczyk, A. Prevalence and impact of autoimmune thyroid disease on myasthenia gravis course. Brain Behav, 2016, 537.
Kaminski, H. J., & Kusner, L. Myasthenia gravis and related disorders. Humana Press, 2018.
Kanazawa, M., Shimohata, T., Tanaka, K.,Nishizawa, M. Clinical features of patients with myasthenia gravis associated with autoimmune diseases. European Journal of Neurology, 2007, 1403-1404.
Kassardjian, C., Murray, B., Kokokyi, S., Jewell, D., Barnett, C., Bril, V., Katzberg, H. Effects of napping on neuromuscular fatigue in myasthenia gravis. Muscle Nerve, 2013, 816-818.
Kulaksizoglu, I. Mood and anxiety disorders in patients with myasthenia gravis; aetiology, diagnosis and treatment. CNS Drugs, 2007, 473-481.
Law, C., Flaherty, C., Bandyopadhyay, S. A Review of Psychiatric Comorbidity in Myasthenia Gravis. Cureus, 2020, 184.
Lázaro, E., Amayra, I., López-Paz, J., Jometón, A., Martín ,N., Caballero, P., De Nicolás, L., Hofmann, H., Kessler, H., Ruiz, B., Martínez, O. Facial afect recognition in myasthenia gravis. Span J Psychol, 2013, 52.
Magni, G., Micaglio, G., Lalli, R., Bejato, L., Candeago, M., Merskey, H., Angelini, C. Psychiatric disturbances associated with myasthenia gravis. Acta Psychiatr Scand, 1988, 443-445.
Martínez-Lapiscina, E., Erro, M., Ayuso, T., Jericó, I. Myasthenia gravis: sleep quality, quality of life, and disease severity. Muscle Nerve, 2012, 174-180.
Millikan, C., Haines, S. The thyroid gland in relation to neuromuscular disease. AMA Arch Intern Med, 1953, 5-39.
Misra, U., Kalita, J., Singh, V., Kumar, S. A study of comorbidities in myasthenia gravis. Acta Neurol Belg., 2020, 59-64.
Nagane, Y., Murai, H., Imai, T., Yamamoto, D., Tsuda, E., Minami, N., Suzuki, Y., Kanai, T., Uzawa, A., Kawaguchi, N., Masuda, M., Konno, S., Suzuki, H., Aoki, M., Utsugisawa, K. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open, 2017, 278.
Nicolle, M., Rask, S., Koopman, W., George, C., Adams, J., Wiebe, S. Sleep apnea in patients with myasthenia gravis. Neurology, 2006, 140-142.
Ohta, K., Shigemoto, K., Fujinami, A., Maruyama, N., Konishi, T., Ohta, M. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur J Neurol, 2007, 1029-34.
Quera-Salva, M., Guilleminault, C., Chevret, S., Troche, G., Fromageot, C., Crowe McCann, C., Stoos, R., De Lattre, J., Raphael, J., Gajdos, P. Breathing disorders during sleep in myasthenia gravis. Ann Neurol, 1992, 86-92.
Raggi, A., Leonardi, M., Antozzi, C., Confalonieri, P., Maggi, L., Cornelio, F., Mantegazza, R. Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis. Neurol Sci, 2010, 41-45.
Ruiter, A., Verschuuren, J., Tannemaat, M. Fatigue in patients with myasthenia gravis. A systematic review of the literature. Neuromuscul Disord, 2020, 631-639.
Sardu, C., Cocco, E., Mereu, A., Massa, R., Cuccu, A., Marrosu, M., Contu, P. Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PLoS One, 2012, 487.
Sieminski, M., Bilińska, M., Nyka, W. Increased frequency of restless legs syndrome in myasthenia gravis. Eur Neurol, 2012, 166-170.
Sneddon, J. Myasthenia gravis – the difcult diagnosis. Br J Psychiatry, 1980, 92-93.
Suzuki, Y., Utsugisawa, K., Suzuki, S., Nagane, Y., Masuda, M., Kabasawa, C., Shimizu, Y., Utsumi, H., Uchiyama, S., Fujihara, K., Suzuki, N. Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study. BMJ Open, 2011, 313.
Thorner, M. Relation of myasthenia gravis to hyperthyroidism. Arch Intern Med (Chic), 1939, 330-335.
Wells, K., Golding, J., Burnam, M. Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry, 1988, 976-981.
Ybarra, M., Kummer, A., Frota, E., Oliveira, J., Gomez, R., Teixeira, A. Psychiatric disorders in myasthenia gravis. Arq Neuropsiquiatr, 2011, 176-179.
Downloads
Published
How to Cite
Issue
Section
ARK
License
Copyright (c) 2023 Bulgarian Neurology
This work is licensed under a Creative Commons Attribution 4.0 International License.
